TQB2825 injection

DRUG2 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Conditions

Follicular LymphomaHematological Tumors

Phase 1

Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Hematological Tumors

Start: 2022-03-22End: 2023-12-31Target: 180Updated: 2022-08-05

Phase 3

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

Not yet recruitingNCT07187960

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Follicular Lymphoma

Start: 2025-11-30End: 2029-02-28Target: 228Updated: 2025-09-23